{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:14:10Z","timestamp":1790194450148,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2017\/25\/N\/NZ7\/01382"],"award-info":[{"award-number":["2017\/25\/N\/NZ7\/01382"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Anthracyclines are widely used anticancer agents with a complex mechanism of action involving topoisomerase II inhibition and DNA intercalation. Despite their clinical efficacy, their use is limited by cancer cell resistance, linked to the formation of secondary alcohol metabolites via carbonyl reductase 1 (CBR1)-mediated reduction. These metabolites exhibit reduced anticancer activity, positioning CBR1 as significant factor in determining therapy outcomes. The study aimed to elucidate the role of CBR1 in mediating the differential responses of various anthracyclines in cancer cells. The role of CBR1 in cancer resistance against five anthracyclines: doxorubicin, daunorubicin, epirubicin, idarubicin, and aclarubicin, was examined in A549 lung cancer cells transduced with the CBR1. Anthracyclines were found to present significant differences in activity related to CBR1 overexpression. Surprisingly, aclarubicin was the most dependent on CBR1 among the tested compounds, while it exhibited a low reaction velocity when catalyzed by recombinant CBR1. The findings reveal critical differences in anthracycline susceptibility to CBR1, offering insights into resistance mechanisms.      <\/jats:p>","DOI":"10.1007\/s12032-025-02893-0","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:14:16Z","timestamp":1752138856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Various anthracyclines exhibit differential cytotoxic effects related to CBR1-induced resistance in lung cancer cells"],"prefix":"10.1007","volume":"42","author":[{"given":"Kamil","family":"Piska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Koczurkiewicz-Adamczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kochanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Bobis-Wozowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedykt","family":"W\u0142adyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"P\u0119kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2893_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s13346-024-01648-0","volume":"15","author":"A Bisht","year":"2025","unstructured":"Bisht A, Avinash D, Sahu KK, et al. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Deliv Transl Res. 2025;15:102\u201333. https:\/\/doi.org\/10.1007\/s13346-024-01648-0.","journal-title":"Drug Deliv Transl Res"},{"key":"2893_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00280-024-04693-1","volume":"94","author":"A Murzyn","year":"2024","unstructured":"Murzyn A, Orze\u0142 J, Obajtek N, et al. Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing. Cancer Chemother Pharmacol. 2024;94:123\u201339. https:\/\/doi.org\/10.1007\/s00280-024-04693-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2893_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells14030169","author":"N Biswal","year":"2025","unstructured":"Biswal N, Harish R, Roshan M, et al. Role of GPCR signaling in anthracycline-induced cardiotoxicity. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14030169.","journal-title":"Cells"},{"key":"2893_CR4","doi-asserted-by":"publisher","first-page":"e14307","DOI":"10.1111\/eci.14307","volume":"54","author":"Z Li","year":"2024","unstructured":"Li Z, Ngu R, Naik AA, et al. Adipocyte maturation impacts daunorubicin disposition and metabolism. Eur J Clin Invest. 2024;54:e14307. https:\/\/doi.org\/10.1111\/eci.14307.","journal-title":"Eur J Clin Invest"},{"key":"2893_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1124\/jpet.113.206805","volume":"347","author":"OS Bains","year":"2013","unstructured":"Bains OS, Szeitz A, Lubieniecka JM, et al. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. J Pharmacol Exp Ther. 2013;347:375\u201387. https:\/\/doi.org\/10.1124\/jpet.113.206805.","journal-title":"J Pharmacol Exp Ther"},{"key":"2893_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.toxlet.2021.02.001","volume":"342","author":"K Piska","year":"2021","unstructured":"Piska K, Jamrozik M, Koczurkiewicz-Adamczyk P, et al. Carbonyl reduction pathway in hepatic in vitro metabolism of anthracyclines: Impact of structure on biotransformation rate. Toxicol Lett. 2021;342:50\u20137. https:\/\/doi.org\/10.1016\/j.toxlet.2021.02.001.","journal-title":"Toxicol Lett"},{"key":"2893_CR7","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1158\/0008-5472.CAN-12-1110","volume":"72","author":"M Jang","year":"2012","unstructured":"Jang M, Kim Y, Won H, et al. Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide. Cancer Res. 2012;72:4214\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1110.","journal-title":"Cancer Res"},{"key":"2893_CR8","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00176","author":"T Matsunaga","year":"2015","unstructured":"Matsunaga T, Kezuka C, Morikawa Y, et al. Up-regulation of carbonyl reductase 1 renders development of doxorubicin resistance in human gastrointestinal cancers. Biol Pharm Bull. 2015. https:\/\/doi.org\/10.1248\/bpb.b15-00176.","journal-title":"Biol Pharm Bull"},{"key":"2893_CR9","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.024711","author":"OS Bains","year":"2009","unstructured":"Bains OS, Karkling MJ, Grigliatti TA, et al. Two nonsynonymous single nucleotide polymorphisms of human Carbonyl Reductase 1 demonstrate reduced in vitro metabolism of Daunorubicin and Doxorubicin. Drug Metab Dispos. 2009. https:\/\/doi.org\/10.1124\/dmd.108.024711.","journal-title":"Drug Metab Dispos"},{"key":"2893_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.01.003","author":"K Piska","year":"2019","unstructured":"Piska K, Koczurkiewicz P, Wnuk D, et al. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells \u2013 The involvement of carbonyl reductase 1 inhibition. Chem Biol Interact. 2019. https:\/\/doi.org\/10.1016\/j.cbi.2019.01.003.","journal-title":"Chem Biol Interact"},{"key":"2893_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cbi.2014.12.019","volume":"234","author":"J Hintzpeter","year":"2015","unstructured":"Hintzpeter J, Hornung J, Ebert B, et al. Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase - Carbonyl reductase 1. Chem Biol Interact. 2015;234:162\u20138. https:\/\/doi.org\/10.1016\/j.cbi.2014.12.019.","journal-title":"Chem Biol Interact"},{"key":"2893_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.fitote.2014.12.010","volume":"101","author":"Y Arai","year":"2015","unstructured":"Arai Y, Endo S, Miyagi N, et al. Structure-activity relationship of flavonoids as potent inhibitors of carbonyl reductase 1 (CBR1). Fitoterapia. 2015;101:51\u20136. https:\/\/doi.org\/10.1016\/j.fitote.2014.12.010.","journal-title":"Fitoterapia"},{"key":"2893_CR13","doi-asserted-by":"publisher","first-page":"120777","DOI":"10.1016\/j.lfs.2022.120777","volume":"305","author":"P Koczurkiewicz-Adamczyk","year":"2022","unstructured":"Koczurkiewicz-Adamczyk P, G\u0105siorkiewicz B, Piska K, et al. Cinnamamide derivatives with 4-hydroxypiperidine moiety enhance effect of doxorubicin to cancer cells and protect cardiomyocytes against drug-induced toxicity through CBR1 inhibition mechanism. Life Sci. 2022;305:120777. https:\/\/doi.org\/10.1016\/j.lfs.2022.120777.","journal-title":"Life Sci"},{"key":"2893_CR14","doi-asserted-by":"publisher","first-page":"113118","DOI":"10.1016\/j.jep.2020.113118","volume":"261","author":"H Zhou","year":"2020","unstructured":"Zhou H, Fu L-X, Li L, et al. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression. J Ethnopharmacol. 2020;261:113118. https:\/\/doi.org\/10.1016\/j.jep.2020.113118.","journal-title":"J Ethnopharmacol"},{"key":"2893_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-011-1768-8","volume":"69","author":"Y Makino","year":"2012","unstructured":"Makino Y, Yamamoto N, Sato H, et al. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer. Cancer Chemother Pharmacol. 2012;69:861\u20139. https:\/\/doi.org\/10.1007\/s00280-011-1768-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2893_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.actbio.2025.02.012","volume":"195","author":"J Ma","year":"2025","unstructured":"Ma J, Zhu R, Li M, et al. Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer. Acta Biomater. 2025;195:421\u201335. https:\/\/doi.org\/10.1016\/j.actbio.2025.02.012.","journal-title":"Acta Biomater"},{"key":"2893_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2016.01.003","author":"J Hintzpeter","year":"2016","unstructured":"Hintzpeter J, Seliger JM, Hofman J, et al. Inhibition of human anthracycline reductases by emodin \u2014 A possible remedy for anthracycline resistance. Toxicol Appl Pharmacol. 2016. https:\/\/doi.org\/10.1016\/j.taap.2016.01.003.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2893_CR18","doi-asserted-by":"publisher","first-page":"0764","DOI":"10.1371\/journal.pbio.0030128","volume":"3","author":"M Tanaka","year":"2005","unstructured":"Tanaka M, Bateman R, Rauh D, et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005;3:0764\u201376. https:\/\/doi.org\/10.1371\/journal.pbio.0030128.","journal-title":"PLoS Biol"},{"key":"2893_CR19","first-page":"4646","volume":"55","author":"B Gonzalez","year":"1995","unstructured":"Gonzalez B, Akman S, Doroshow J, et al. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res. 1995;55:4646\u201350.","journal-title":"Cancer Res"},{"key":"2893_CR20","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160614","author":"OS Bains","year":"2010","unstructured":"Bains OS, Karkling MJ, Lubieniecka JM, et al. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010. https:\/\/doi.org\/10.1124\/jpet.109.160614.","journal-title":"J Pharmacol Exp Ther"},{"key":"2893_CR21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m508343200","author":"E Salvatorelli","year":"2006","unstructured":"Salvatorelli E, Guarnieri S, Menna P, et al. Defective one- or two-electron reduction of the anticancer Anthracycline Epirubicin in human heart. J Biol Chem. 2006. https:\/\/doi.org\/10.1074\/jbc.m508343200.","journal-title":"J Biol Chem"},{"key":"2893_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jhep.2010.06.045","volume":"54","author":"E Tak","year":"2011","unstructured":"Tak E, Lee S, Lee J, et al. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol. 2011;54:328\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2010.06.045.","journal-title":"J Hepatol"},{"key":"2893_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cbi.2008.07.002","volume":"176","author":"A Rogalska","year":"2008","unstructured":"Rogalska A, Koceva-Chy\u0142a A, J\u00f3\u017awiak Z. Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chem Biol Interact. 2008;176:58\u201370. https:\/\/doi.org\/10.1016\/j.cbi.2008.07.002.","journal-title":"Chem Biol Interact"},{"key":"2893_CR24","doi-asserted-by":"publisher","first-page":"114813","DOI":"10.1016\/j.bcp.2021.114813","volume":"193","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yang C, Zhong W, et al. Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. Biochem Pharmacol. 2021;193:114813. https:\/\/doi.org\/10.1016\/j.bcp.2021.114813.","journal-title":"Biochem Pharmacol"},{"key":"2893_CR25","first-page":"245","volume":"7","author":"J Dong","year":"1995","unstructured":"Dong J, Naito M, Tatsuta T, et al. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol Res. 1995;7:245\u201352.","journal-title":"Oncol Res"},{"key":"2893_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/bjc.1996.621","volume":"74","author":"G Lehne","year":"1996","unstructured":"Lehne G, De Angelis P, Clausen OPF, Rugstad HE. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Br J Cancer. 1996;74:1719\u201329. https:\/\/doi.org\/10.1038\/bjc.1996.621.","journal-title":"Br J Cancer"},{"key":"2893_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/CAD.0000000000001283","volume":"33","author":"TP Brouwer","year":"2022","unstructured":"Brouwer TP, van der Zanden SY, van der Ploeg M, et al. The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer. Anticancer Drugs. 2022;33:614\u201321. https:\/\/doi.org\/10.1097\/CAD.0000000000001283.","journal-title":"Anticancer Drugs"},{"key":"2893_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00903.x","author":"S Lal","year":"2008","unstructured":"Lal S, Sandanaraj E, Wong ZW, et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00903.x.","journal-title":"Cancer Sci"},{"key":"2893_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/00498254.2024.2330493","volume":"54","author":"NF Ebaid","year":"2024","unstructured":"Ebaid NF, Abdelkawy KS, Shehata MA, et al. Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients. Xenobiotica. 2024;54:160\u201370. https:\/\/doi.org\/10.1080\/00498254.2024.2330493.","journal-title":"Xenobiotica"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02893-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02893-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02893-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:02:42Z","timestamp":1753938162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02893-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2893"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02893-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}